Noramco, Inc. – FDA 483, Oct 15, 2025

Noramco, LLC. underwent an FDA inspection from October 7 to October 15, 2025, resulting in the issuance of a Form 483. This document details observations of objectionable conditions at their Wilmington, DE drug substances manufacturing facility, indicating areas requiring prompt attention for regulatory compliance. Two significant issues were identified.

First, documented manufacturing production weighing records were found to be inaccurate. Gross weights on drug substance intermediate container labels were calculated based on nominal weights rather than actual weighing operations. These unverified weights were then used as starting materials in subsequent manufacturing processes without further accuracy checks.

Second, the firm's equipment calibration procedures were deficient. The calibration program lacked acceptance criteria and requirements to calibrate equipment across its intended use ranges. For instance, a production balance was observed with an operational range exceeding its maximum calibrated weight, and a high measurement uncertainty was accepted without adjusting its intended use, despite its critical role in weighing raw materials. These observations, issued under the Federal Food, Drug and Cosmetic Act, necessitate that Noramco, LLC. address these practices and implement corrective actions to ensure product quality and regulatory adherence.